We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

New Blood Test Identifies People at Risk of Developing Blood Cancers

By LabMedica International staff writers
Posted on 28 Aug 2023
Print article
Image: The tool can identify individuals at risk of developing different myeloid leukaemias (Photo courtesy of 123RF)
Image: The tool can identify individuals at risk of developing different myeloid leukaemias (Photo courtesy of 123RF)

The myeloid neoplasms form a group of interconnected cancers encompassing acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Although treatments for these cancers have advanced in recent years, the majority of cases remain without a cure. Recent scientific discoveries have revealed that these cancers develop slowly over decades through the accumulation of DNA mutations in blood stem cells, which are responsible for normal blood formation. These mutations prompt these stem cells to grow faster than usual, and as additional mutations gather, they can lead to leukemia. Fortunately, while mutations promoting cell growth are prevalent, only a small subset of cases progresses to leukemia. Detecting these cases at an early stage could be vital in preventing the development of these cancers. Scientists have now developed a novel test to identify individuals at risk of developing acute myeloid leukemia and related cancers, years before their onset.

Researchers at the University of Cambridge (Cambridge, UK) along with their colleagues have introduced a new platform named 'MN-predict.' This platform empowers doctors and researchers to identify individuals at risk and devise new treatments to prevent the emergence of these potentially life-threatening cancers. The team examined data from over 400,000 individuals to create "MN-predict," a predictive tool capable of assessing the likelihood of developing blood cancers within a 10-15-year timeframe. This test involves patients providing a blood sample from which DNA is extracted and sequenced on a limited scale, along with basic blood cell counts. Armed with this information, the platform identifies those with a high risk of developing any of these cancers. Its application can be integrated into specialized clinics dedicated to leukemia prevention.

“We all know that prevention is better than cure, but it is not easy to prevent diseases like leukemia without knowing who is at risk,” said Professor George Vassiliou, senior author of the study. “MN-predict makes it possible to identify at-risk individuals, and we hope it can become an essential part of future leukemia prevention programs.”

Related Links:
University of Cambridge

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.